5/2/2023 0 Comments Novamind redditForward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. This does not constitute an offer to sell or a solicitation of offers to buy any securities.ĭisclaimer for Forward-Looking Statements NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness. Lobe Sciences is a life sciences company focused on psychedelic medicines. I look forward to keeping our shareholders informed as the year unfolds. This is a major step forward as the team works to develop the industry leading platform for use with psychedelic and virtual therapy and counseling content in physician offices and clinics as well as integrating into the newly expanding Metaverse. Our joint venture with Virtual Psychedelics Inc., which is developing the Krysalis system, has completed the development of an early-stage prototype of the Krysalis Pod System. Affirming our access to current good manufacturing practice (“cGMP”) pharmaceutical grade active pharmaceutical ingredients (API) will enable us to efficiently conduct clinical trials and plan for further work using differentiated compounds. We have secured an exclusive source of L-130 and a series of related compounds for use in clinical trials this year and for subsequent trials in the future. Following the successful completion of the first-in-man safety trials, a Phase Ib/IIa study will be implemented in healthy volunteers and patients.īe the first to know when breaking news are released. Lobe will investigate the safety and tolerability of an oral drug candidate, L-130 (a molecular modification of naturally occurring psilocin) and measure absolute pharmacokinetics of this new chemical entity (NCE) given alone and in conjunction with NAC. Following FDA’s input, an IND will be filed and Phase I clinical trials in healthy subjects will be initiated immediately thereafter. We expect to have this meeting in the 3 rd quarter of 2022. Lobe is preparing a pre-IND meeting request with the US Food and Drug Administration (FDA) to confirm its regulatory strategy and Phase I clinical protocols. Our patent pending combination therapy may allow for the use of sub-psychedelic dosing while retaining efficacy on these and other disorders.” The combinations of psilocybin with n-acetyl cysteine (NAC) delivered superior results compared to either drug alone. Preclinical models have shown statistically significant results in the treatment of PTSD and mTBI caused by induced trauma. ![]() The next 12 months will see the culmination of investments we’ve made in the development of therapeutics to treat neurological diseases such as Post Traumatic Stress Disorder (PTSD) and mild Traumatic Brain Injury (mTBI). Philip Young CEO and Director stated, “I am happy to report that we have made significant progress since our last update in Q3 last year. (CSE: LOBE) (OTCQB: LOBED) (“Lobe”), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder of 2022 and into 2023. Vancouver, British Columbia–(Newsfile Corp.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |